Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong
treatment is required and there is no cure. HIV can integrate in the host genome and persist …

Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or
to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will …

Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and …

The response to coronavirus disease 2019 (COVID-19) appears no different. We are not
aware of any gender analysis of the outbreak by global health institutions or governments in …

Attempts to reduce the human immunodeficiency virus type 1 (HIV-1) reservoir and induce
antiretroviral therapy (ART)-free virologic control have largely been unsuccessful. In this …

Abstract HIVACAT T-cell immunogen (HTI) is a novel human immunodeficiency virus (HIV)
vaccine immunogen designed to elicit cellular immune responses to HIV targets associated …

Human immunodeficiency virus type 1 (HIV-1) infection persists despite years of
antiretroviral therapy (ART). To remove the stigma and burden of chronic infection …

Background The administration of broadly neutralising anti-HIV-1 antibodies before latency
reversal could facilitate elimination of HIV-1-infected CD4 T cells. We tested this concept by …

Kick&kill strategies combining drugs aiming to reactivate the viral reservoir with therapeutic
vaccines to induce effective cytotoxic immune responses hold potential to achieve a …

Efforts to cure HIV have focused on reactivating latent proviruses to enable elimination by
CD8+ cytotoxic T-cells. Clinical studies of latency reversing agents (LRA) in antiretroviral …